Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Listerin E3 ubiquitin-protein ligase 1 (LTN1)
- Target
- LTN1
- Molecular classification
- Enzyme, E3 ubiquitin-protein ligase, RING finger protein, Zinc finger protein
01
Overview
Listerin E3 ubiquitin-protein ligase 1 (LTN1) is a RING-type E3 ubiquitin ligase essential for the ribosome-associated quality control (RQC) pathway[1]. This enzyme is recruited to 60S ribosomal subunits containing stalled translation products, where it mediates the polyubiquitination of associated aberrant polypeptides, marking them for proteasomal degradation and preventing the build-up of cytotoxic misfolded or incomplete proteins[1][2]. LTN1 activity is critical for maintaining protein homeostasis and neuronal health, with genetic deficiencies linked to neurodegenerative phenotypes and pathogenic protein aggregation in disease models. LTN1’s function is supported by auxiliary factors such as NEMF, and its failure can result in the accumulation of toxic translation products, underlying its importance in neurological disorders[1][2][3].
- Other names
- C21orf10C21orf98KIAA0714RNF160ZNF294HSPC087FLJ11053RING finger protein 160Zinc finger protein 294E3 ubiquitin-protein ligase listerinRING-type E3 ubiquitin transferase listerinLISTERIN
02
Mechanism of action
Not established for direct small-molecule modulators; the mechanism in potential therapeutic context would involve modulation of E3 ubiquitin ligase activity and enhancement or inhibition of ribosome-associated degradation
03
Biological functions
Ribosome-associated quality controlUbiquitin-mediated protein degradationProteostasis maintenanceRemoval of aberrant or stalled nascent peptide chainsPrevention of cytotoxic protein aggregation
04
Disease associations
Neurodegenerative diseaseProtein aggregation disordersPossibly other proteostasis-related diseases
05
Safety considerations
No known safety issues as a direct drug target, but genetic loss-of-function leads to neurodegeneration in model organisms and proteostasis imbalance[1]
06
Biomarkers
No established clinical biomarkers; loss or dysfunction of LTN1 used as an experimental readout for certain models of neurodegeneration[1]
Beyond the preview
Go deeper on Listerin E3 ubiquitin-protein ligase 1 (LTN1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Listerin E3 ubiquitin-protein ligase 1 (LTN1).